Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

DBCOND0093009Hematologic Neoplasms

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: Relapsed or Refractory Diffuse Large B Cell Lymphoma · Relapsed/Refractory Diffuse Large B Cell Lymphoma · Relapsed /Refractory Diffuse Large B Cell Lymphoma · Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Relapsed/Refractory Large B Cell Lymphoma
Classified under: Hematologic Neoplasms
Indicated drugs: Glofitamab

What you can answer from here — as of October 22, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

37Clinical trialsPhase, status and sponsor resolved per trial

3Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account